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Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has been 
a longstanding challenge for head and neck oncologists, and current treatments still 
have limited efficacy. ERK is aberrantly overexpressed and activated in HNSCC. 
Herein, we aimed to investigate the cause of the limited therapeutic effect of selu-
metinib, a selective inhibitor of MEK in HNSCC, as MEK/ERK reactivation inevitably 
occurs. We assessed the effects of combining selumetinib with fibroblast growth 
factor receptor 3 (FGFR3) inhibitor (PD173074) on tumor growth. Selumetinib tran-
siently inhibited MAPK signaling and reactivated ERK signaling in HNSCC cells. 
Rebound in the ERK and Akt pathways in HNSCC cells was accompanied by increased 
FGFR3 signaling after selumetinib treatment. Feedback activation of FGFR3 was a 
result of autocrine secretion of the FGF2 ligand. The FGFR3 inhibitor PD173074 pre-
vented MAPK rebound and sensitized the response of HNSCC cells to selumetinib. 
These results provided rational therapeutic strategies for clinical studies of this sub-
type of patients that show a poor prognosis with selumetinib. Our data provide a 
rationale for combining a MEK inhibitor with inhibitors of feedback activation of 
FGFR3 signaling in HNSCC cells. ERK rebound as a result of the upregulation of 
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1  | INTRODUC TION
Head and neck squamous cell carcinoma is the sixth leading can-
cer by incidence worldwide.1 Despite high cure rates in early- stage 
HNSCC with either surgery or radiotherapy, nearly 60% of HNSCC 
patients still present with locally advanced- stage disease.2
In HNSCC, multiple mutations or aberrant overactivation of the 
epidermal growth factor receptor (EGFR)- MEK signaling pathway 
has been frequently observed.3,4 EGFR expression is detected in 
>90% of HNSCC and frequently triggers the RAS/RAF/MEK/ERK 
cascade. Clinical and biological evidence has suggested that the 
ERK pathway may play a pivotal role in tumor progression. ERK 
hyperactivation was investigated in general for cancers harboring 
RTK dysregulation, or KRAS or BRAF mutations.5 In HNSCC, ERK 
overexpression was observed in tumor cells as well as in infiltrating 
lymphoid cells.5 ERK expression and activation was reported to be 
associated with clinicopathological parameters and cell proliferation 
in oral tongue squamous carcinoma.5,6
ERK inhibition could be an attractive strategy for anticancer ther-
apies against thyroid cancer or advanced melanoma. Indeed, MEK 
and RAF inhibitors are compatible therapeutic agents for tumors 
addicted to ERK signaling. However, acquired resistance to these 
inhibitors and other targeted therapeutics can emerge in tumor 
cells. Several groups have investigated the mechanism of intrinsic 
(that is, present before treatment) or acquired resistance (acquired 
during treatment by various therapy- induced adaptive responses) 
against ERK blockades in many cancers. Selumetinib (AZD6244), a 
MEK1/2 inhibitor, provoked intrinsic resistance by PI3K signaling 
in colorectal cancer cells with KRAS or BRAF mutations.7,8 Some 
studies have generated evidence that acquired resistance to MEK 
inhibition induces feedback activation of several RTK called “kinome 
reprogramming” through the inhibition of a physiological negative 
loop.9,10 Currently, adaptive resistance to MEK inhibition is thought 
to be driven by feedback activation of fibroblast growth factor re-
ceptor 1 (FGFR1) among the RTK in KRAS- mutant lung cancer.11,12 
However, the mechanism associated with acquired resistance to 
MEK inhibition has not been clearly determined.
Data from numerous studies have shown that ERK activation was 
intimately associated with acquired- resistance mechanisms. ERK- 
activity rebound appeared at an early phase after treatment with the 
RAF inhibitor vemurafenib in BRAF- mutant thyroid cancer cell lines 
resistant to vemurafenib, and this resistance was overcome using 
combination treatment with the HER kinase inhibitor lapatinib.13 
Rapid recovery of ERK signaling has also been shown in melanoma 
cells and papillary thyroid cancer cells in the presence of a BRAF 
inhibitor.14,15
Based on MAPK activation in HNSCC, many strategies have 
been developed to suppress MAPK activity. Small- molecule MEK 
inhibitors represent the most specific and effective strategy 
tested to date in several cancers. Although preclinical data are 
extensive, objective response rates in these studies have been 
modest.16 Herein, we investigated the acquired resistance of a 
MEK inhibitor in several oral tongue cancer cell samples express-
ing high levels of ERK. MEK inhibition promoted an ERK rebound 
during early phase treatment, which was due to feedback- induced, 
ligand- dependent activation of FGFR3 signaling. RTK FGFR3 is 
another target for which researchers are currently developing 
inhibitors. The current study was designed to explore whether 
feedback activation of FGFR3 occurs after MEK inhibition and 
whether combined inhibition of FGFR3 and MEK is a promising 
treatment strategy for HNSCC.
2  | MATERIAL S AND METHODS
2.1 | Ethics statement
All animal experiment protocols were approved by the commit-
tee of ethics on animal research of Yonsei University College of 
Medicine (Accession No. 2014- 0366). All mice were treated in ac-
cordance with the guidelines for the care and use of laboratory 
animals of the institutional animal care and use committee at our 
institute.
2.2 | Cell lines and reagents
Cal27 human tongue squamous cell carcinoma cell line and 
FADU human hypopharyngeal squamous cell carcinoma cell 
line were purchased from the ATCC (Manassas, VA, USA). HN6 
human tongue squamous cell carcinoma cell line was kindly pro-
vided by Dr Kim (Ajou University, Suwon, Korea). Cal27 and HN6 
cells were maintained in DMEM (Lonza) supplemented with 10% 
FBS and 1% penicillin/streptomycin. FADU cells were cultured in 
RPMI- 1640 (Lonza, Walkersville, MD, USA) supplemented with 
10% FBS and 1% penicillin/streptomycin (Invitrogen, Carlsbad, 
CA, USA). All cell lines were cultured in a humidified atmos-
phere of 5% CO2 at 37°C. AZD6244 was purchased from Selleck 
Chemicals, and PD173074 was purchased from Sigma- Aldrich (St 
Louis, MO, USA).
FGFR3 and the ligand FGF2 diminished the antitumor effects of selumetinib, which 
was overcome by combination treatment with the FGFR3 inhibitor.
K E Y W O R D S
fibroblast growth factor receptor, head and neck cancer, MAP kinase signaling system, MEK 
inhibition, receptor cross-talk
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2.3 | Receptor tyrosine kinase array
Phospho- RTK array assay was carried out according to the manu-
facturer’s instructions (PathScan Antibody Array Kit, Fluorescent 
Readout; Cell Signaling Technology, Danvers, MA, USA). Cells were 
lysed in cell lysis buffer (Cell Signaling Technology). Briefly, 30- 
150 μg of each lysate was incubated with blocked arrays overnight 
at 4°C in an orbital shaker. After washing with the provided buffer, 
the arrays were incubated for 2 hours at room temperature with a 
1× detection antibody cocktail and subsequently with streptavidin- 
conjugated DyLight680 (Thermo Fisher Scientific, Rockford, IL, 
USA) for 30 minutes at room temperature. After washing with array 
wash buffer, fluorescent signals were detected using a fluorescent 
digital imaging system capable of excitation at 680 nm and detec-
tion at 700 nm.
2.4 | Clonogenic assay
Cells were seeded at 2- 5 × 104 cells/well in six- well plates and ex-
posed to the indicated drugs for 24 hours. The culture medium 
was replaced every 3 days. After 14- 21 days, the cells were fixed 
in 4% paraformaldehyde (PFA) and stained with 0.1% crystal violet. 
Colonies containing at least 50 individual cells were counted using a 
stereomicroscope.
2.5 | Immunoblotting
Cells were washed twice with ice- cold PBS and lysed in ice- cold Tris 
buffer (10 mmol/L Tris- HCl [pH 7.4], 100 mmol/L NaCl, 1 mmol/L 
EDTA, 1 mmol/L EGTA, 1 mmol/L NaF, 20 mmol/L Na4P2O7, 
2 mmol/L Na3VO4, 1% Triton X- 100, 10% glycerol, 0.1% SDS, and 
0.5% deoxycholate; Invitrogen) containing 1 mmol/L PMSF and a 
protease inhibitor cocktail (Sigma). Cell lysates were centrifuged 
and then mixed with SDS- containing sample buffer followed by boil-
ing for 5 minutes. Whole- cell extracts (25 μg/lane) were separated 
by 10% SDS- PAGE and electrotransferred to a PVDF membrane 
(Millipore, Burlington, MA, USA). Antibodies against anti- phospho 
FGFR3 (1: 500), - FGFR3 (1: 500), - phospho Akt (1: 500), - Akt (1: 
1000), - phospho ERK (1: 1000), - ERK (1: 1000), - Caspase 3 (1: 1000), 
and GAPDH (1: 2000) were used for immunoblotting. All of these 
antibodies were purchased from Cell Signaling Technology, Inc.
2.6 | Cell viability assay
Cell Counting Kit- 8 (Dojindo Molecular Technologies, Inc., Rockville, 
MD, USA) was used to determine cell viabilities, according to the 
manufacturer’s instructions. Cells were plated in a 96- well plate at a 
density of 104 cells/well. After serum starvation, cells were treated 
with the indicated drugs for the indicated times or concentrations 
before adding CCK- 8 solution (a water- soluble tetrazolium salt). 
Cells were incubated for 1- 2 hours, and the absorbance at 450 nm 
was measured using a microplate reader (Molecular Devices, San 
Jose, CA, USA).
2.7 | Silencing of FGFR3 and FGF2
Cells were transfected with 100 nmol/L FGFR3 siRNA and 50 nmol/L 
FGF2 siRNA or a control siRNA (Santa Cruz Biotechnology, Dallas, 
TX, USA) using Lipofectamine RNAiMAX (Invitrogen) and incubated 
for 24 hours at 37°C in a humidified 5% CO2 incubator. FGFR3 
siRNA and FGF2 siRNA were designed and synthesized by Bioneer 
(Deajeon, Korea; sequences of FGFR3 siRNA and FGF2 siRNA can 
be seen in Table S1, Data S1).
2.8 | Enzyme- linked immunosorbent assay
Cells were collected for the measurement of FGF2 concentration 
by FGF2 ELISA kit (Catalog no. ab99979, Abcam, Cambridge, UK). 
Assays were carried out according to the manufacturer’s instruc-
tions in a 96- well plate.
2.9 | Cell cycle analysis
Cell cycle progression was analyzed by propidium iodide (PI; Sigma) 
staining and flow cytometry. After drug treatment, the cells were 
trypsinized and washed in ice- cold PBS. After fixation in 70% etha-
nol, the cells were suspended in PI solution (50 μg/mL) containing 
DNase- free RNase (1 μg/mL) and incubated for 30 minutes at 37°C. 
Measurement of the cellular DNA content was carried out using a BD 
FACSVerse flow cytometer (Becton Dickinson Immunocytometry 
Systems, San Jose, CA, USA) and analyzed using FlowJo v10 soft-
ware (FlowJo, Ashland, OR).
2.10 | Apoptosis assay
Apoptosis was assessed by Annexin V- FITC (BD Biosciences 
Pharmingen, San Diego, CA, USA) dual staining. After drug treat-
ment, cells were harvested by trypsinization. The cells were washed 
with ice- cold PBS and then washed with 1× binding buffer. Cells were 
then labeled with Annexin V- FITC according to the manufacturer’s 
instructions. Apoptotic cells were analyzed using a BD FACSVerse 
flow cytometer (Becton Dickinson Immunocytometry Systems). 
For TUNEL assays, cells were seeded on glass coverslips in six- well 
plates and treated with drugs. After treatment, cells were fixed 
with 4% PFA and analyzed using the In Situ Cell Death Detection 
Kit (Roche Diagnostics, Mannheim, Germany). Apoptotic cells were 
detected according to the manufacturer’s instructions. Slides were 
visualized with a Zeiss AxioVert 200 inverted epifluorescence micro-
scope. Images were captured with an AxioCam digital microscope 
camera and analyzed with AxioVision software (Carl Zeiss Vision, 
Oberkochen, Germany).
2.11 | Orthotopic xenograft mouse model
Cal27 cells were harvested from subconfluent cultures by trypsiniza-
tion and washed with serum- free medium. Cal27 cells (5 × 105/30 μL) 
were inoculated directly onto the anterior tongues of 6- week- old male 
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nude mice (Orientbio Inc., Seongnam- si, Korea) using a Hamilton syringe 
(Hamilton Company, Reno, NV, USA). Mice were then randomized into 
four groups (4 mice/group). Tumors developed for 14 days. The mice 
were treated twice per week for 28 days by i.p. injection with DMSO 
(vehicle control), 20 mg/(kg day) AZD6244, 10 mg/(kg day) PD173074, 
or 10 mg/(kg day) PD173074 at 1 day post- injection of 20 mg/(kg day) 
AZD6244. Tumor volumes were calculated as (length × width2) × 0.5. 
The mice were weighed once a week, and tumor growth was measured 
weekly using a digimatic caliper (Mitutoyo Co., Kawasaki-shi, Japan). 
The mice were killed 52 days post- injection, and tumors were har-
vested to carry out histopathology and biochemical assays. Samples 
were fixed overnight in neutral buffered formalin, and immunohis-
tochemical staining was carried out using tumor tissues and primary 
antibodies against Ki67, p- FGFR3, p- Akt, p- ERK, and cleaved caspase 
F IGURE  1 MEK inhibitor induced an ERK- activity rebound and fibroblast growth factor receptor 3 (FGFR3) activation. A, Phosphorylated 
ERK and total ERK protein expression are shown in a representative western blot. Head and neck squamous cell carcinoma (HNSCC) cell 
lines were treated with 0.5 μmol/L AZD6244 or 0.1% DMSO as a vehicle control for different durations. AZD6244 was replaced with fresh 
media at the indicated times. GAPDH was detected as a loading control. B, Phospho- RTK assay in Cal27 cells treated with AZD6244 for 
6 h. Cal27 cells incubated with 0.1% DMSO for 6 h served as a control. C, Representative western blot analysis of FGFR3, Akt, and ERK 
expression in Cal27 cells after treatment with 0.5 μmol/L AZD6244 for different time periods. Media containing AZD6244 was replaced 
with fresh media (lacking AZD6244) at the indicated times. GAPDH was detected as a loading control. D, Cell growth was measured in 
Cal27 cells treated with AZD6244 or PD173074 as an FGFR inhibitor in cell- viability assays. Cells were treated for 48 h with 0.1% DMSO, 
0.5 μmol/L AZD6244 alone, 1 μmol/L PD173074, or 0.5 μmol/L AZD6244 with 1 μmol/L PD173074. Bars represent means ± SEM between 
replicates (n = 3). Significant differences compared to the corresponding controls, *P < .05. E, Clone- formation ability of Cal27 cells treated 
with AZD6244 was evaluated in clonogenic assays. Cal27 cells were treated with a dose gradient of AZD6244 in the absence or presence 
of 1 μmol/L PD173074 for 14 d and were studied in clonogenic assays. Bars represent means ± SEM between replicates (n = 3). Significant 
differences compared to the corresponding controls, **P <  .01
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3. Immunostained sections were analyzed by Allred score under a 
Nikon light microscope (Nikon, Tokyo, Japan) (Data S1).17 Microscopy 
images were captured using AxioCam digital microscope cameras and 
AxioVision image processing (Carl Zeiss Vision).
2.12 | In vivo fluorescence imaging
Mice were injected with MMPsense 680 (PerkinElmer, Waltham, MA, 
USA) by tail vein injection. At 24 hours post- injection, the mice were 
imaged using an IVIS Spectrum instrument (Caliper LifeSciences, 
Waltham, MA, USA) while under anesthesia using isoflurane in oxygen. 
Fluorescence images were recorded with a 1- second exposure using 
a 700/10 nm filter after excitation at 680 nm. Autofluorescence was 
removed using IVIS Spectrum Living Imaging Software.
2.13 | Statistical analysis
All data are represented as mean ± SD from three experiments car-
ried out in triplicate. Comparative statistical analyses were done with 
Student’s t test and one- way analysis of variance using SPSS 20.0 
statistical software (SPSS, Chicago, IL, USA). P- values <0.05 were 
considered statistically significant (*P < .05; **P < .01; ***P < .001).
F IGURE  2 Knockdown of fibroblast growth factor receptor 3 (FGFR3) abrogated ERK rebound and cell growth in head and neck squamous 
cell carcinoma (HNSCC) cells treated with AZD6244. A, Relative FGFR3, Akt, and ERK expression levels in Cal27 cells transfected with siFGFR3 
or a scrambled oligo control (siControl) for 48 h, and treated with AZD6244 are shown by representative western blot analysis. HNSCC 
cell lines were treated with 0.5 μmol/L AZD6244 or 0.1% DMSO for different time periods. Media containing AZD6244 was replaced with 
fresh media (lacking AZD6244) at the indicated times. GAPDH was detected as a loading control. B, IC50 of AZD6244 in HNSCC cell lines. 
Concentrations of AZD6244 (μmol/L) that inhibited the viability of Cal27, HN6, and FADU cells by 50% (IC50) after 72 h were determined by 
MTT assays. Each value represents mean ± SEM from three independent experiments, carried out in triplicate. C, Cell growth was measured by 
cell viability assays with Cal27 cells treated as described in (A). Bars represent means ± SEM between replicates (n = 3). Significant differences 
compared to the corresponding controls, *P  < .05. D, FGF2 expression in Cal27 cells treated with AZD6244 was determined using an FGF2 
ELISA kit, as described in Materials and Methods. Cal27 cells were treated with AZD6244 for the indicated times. Bars represent means ± SEM 
between replicates (n = 3). Significant difference compared to the control, *P  < .05. E, FGFR3, Akt, and ERK expression in Cal27 cells 
transfected with siFGF2 or siControl for 48 h, and treated with AZD6244 at the indicated times are shown with a representative western blot
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3  | RESULTS
3.1 | Extracellular signal- regulated kinase 
reactivation in MEK inhibitor- treated HNSCC cells
Recent reports have indicated that ERK activation is frequently 
dysregulated in cancer cells and is associated with anticancer- drug 
resistance. Therefore, we investigated whether the ERK pathway is 
related to resistance in HNSCC using AZD6244 as a selective MEK 
inhibitor to inhibit the ERK pathway. We used three cell lines: Cal27 
cells and HN6 cells (established from human tongue carcinomas) and 
FADU cells (established from a human hypopharyngeal carcinoma). 
The cells were treated with AZD6244 for the indicated durations, 
after which the medium was replaced with fresh medium lack-
ing AZD6244 (Figure 1A). Results showed that ERK activation re-
bounded transiently within a few hours after AZD6244 treatment in 
HNSCC cell lines. ERK activity disappeared shortly after treatment, 
but resurged over time, even though the Cal27 and HN6 cell lines 
showed differences in the time period before the ERK rebound oc-
curred (Figure 1A). FADU cells did not show an ERK rebound within 
24 hours.
Next, to determine whether RTK are related to the ERK 
 rebound after MEK inhibition, a phospho- RTK array was car-
ried out in Cal27 cells after a 6- hour treatment with AZD6244 
(Figure 1B). In cells treated with AZD6244, FGFR3 expression was 
elevated among RTK and some factors involved in downstream 
signal- transduction pathways. Our western blot results showed 
that ERK reactivation was accompanied by increased FGFR3 ac-
tivity under MEK inhibition, where phosphorylated FGFR3 levels 
increased, but total FGFR3 levels did not show any change after 
AZD6244 treatment (Figure 1C, results of HN6 and FADU cells 
can be seen in Figure S1). Using PD173074 as an FGFR3 inhibi-
tor, we evaluated the effect of FGFR3 activity on cell proliferation 
when cells were exposed to the MEK inhibitor. Combined treat-
ment with AZD6244 and PD173074 attenuated cell proliferation 
significantly more than treatment with AZD6244 or PD173074 
alone (P < .05). Treatment with AZD6244 or PD173074 alone did 
not influence cell growth itself (Figure 1D). After a dose gradient 
exposure to AZD6244, combination treatment with PD173074 
clearly reduced the number of colonies more so than did AZD6244 
treatment alone (Figure 1E). These results showed that coinhibi-
tion of MEK and FGFR3 may synergistically increase the sensitiv-
ity of HNSCC cells to AZD6244.
3.2 | MEK inhibition upregulated FGFR3
To further investigate whether FGFR3 activation is effective against 
the AZD6244- induced ERK- activity rebound, siRNA against FGFR3 
was used in Cal27 cells. We showed that the ERK- activity rebound 
arose under MEK inhibition and that the p- FGFR3 level increased 
gradually in Cal27 cells. When FGFR3 expression weakened, the 
ERK- activity rebound began to diminish at 6 hours post- AZD6244 
treatment in Cal27 cells (Figure 2A, results of HN6 cells can be 
seen in Figure S2). As a result of the AZD6244 half- maximal in-
hibitory concentration (IC50) in HNSCC cells, Cal27 cells (AZD6244 
IC50, 1.33 μmol/L) showed a higher IC50 than observed in HN6 
cells (AZD6244 IC50, 0.58 μmol/L) or FADU cells (AZD6244 IC50, 
1.16 μmol/L), but these differences were not significant (Figure 2B). 
After siFGFR3 transfection, proliferation of Cal27 cells was signifi-
cantly reduced compared to that of control transfectants treated 
with scrambled siRNA (Figure 2C). Next, we explored FGF2 expres-
sion under MEK inhibition to determine the role of FGF2 in FGFR3 
activation. FGF2, referred to as basic FGF, is a major ligand of FGFR3. 
In Cal27 cells, FGF2 level in the media increased time- dependently 
after treatment with AZD6244 (Figure 2D). In FGF2 siRNA trans-
fectants, the p- FGFR3 level decreased and the ERK rebound also 
reduced, suggesting that FGF2 mediated FGFR3 feedback activation 
during MEK inhibition (Figure 2E). To rule out the off- target effects, 
two different siFGFR3 and siFGF2 were transfected to Cal27 cells as 
shown in Figure S3 and the representative result is shown in Figure 2.
3.3 | Fibroblast growth factor receptor 3 
inhibition and MEK inhibition induced apoptotic 
cell death
To explore the mechanism by which FGFR3 inhibition retarded cell 
proliferation, we analyzed cell cycle progression in Cal27 cells by 
flow cytometry. Sub- G1 distribution following combination treat-
ment with AZD6244 and PD173074 increased, which represented 
delayed cell proliferation due to apoptotic cell death (Figure 3A, 
histogram can be seen in Figure S4). Next, we used the selective 
FGFR3 inhibitor PD173074 to investigate whether FGFR3 inhibi-
tion affected the ERK rebound and could inhibit cell growth in 
AZD6244- treated Cal27 cells. After treatment with AZD6244 alone, 
the p- FGFR3 level increased and the ERK rebound was evoked, but 
not after treatment with both AZD6244 and PD173074. Treatment 
with PD173074 and AZD6244 attenuated the ERK rebound in Cal27 
cells. Level of cleaved caspase 3 did not increase following AZD6244 
treatment alone, but increased significantly after combined treat-
ment with PD173074. A trend of increased caspase 3 cleavage after 
combination treatment was observed in Cal27 cells (Figure 3B, re-
sults of HN6 cells can be seen in Figure S5). Next, apoptotic cells 
were quantified by Annexin V/PI staining. Combined treatment 
significantly increased the apoptotic index compared to treatment 
with AZD6244 alone. After treating cells with AZD6244, the pro-
portion of apoptotic cells was 9.4 ± 1.5% in Cal27 cells. However, 
the proportion of apoptotic cells after combined treatment with 
AZD6244 and PD173074 was 21.2 ± 2.4% (Cal27 cells), suggesting 
that an additive effect was observed with AZD6244 and PD173074 
(Figure 3C). Furthermore, we found that DNA fragmentation sig-
nificantly increased after combined treatment compared with that 
observed after treatment with AZD6244 or PD173074 alone. DNA 
fragmentation was determined in TUNEL assays. Coinhibition of 
FGFR and MEK resulted in an increased number of TUNEL- positive 
cells. Apoptosis was induced significantly by the combination treat-
ment (Figure 3D).
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3.4 | Combination of FGFR inhibitor and MEK 
inhibitor leads to antitumor activity in vivo
We observed synergistic effects following combination treatment 
with the MEK inhibitor and FGFR inhibitor in vitro. To test whether 
FGFR inhibition could be an effective strategy for controlling resist-
ance to MEK inhibition in vivo, we used an orthotopic xenograft 
mouse model of HNSCC. Cal27 cells were injected into the tongue 
of nude mice and tumor volume was evaluated on day 14. Mice were 
i.p. injected with vehicle, AZD6244, or both inhibitors in combination 
twice weekly (n = 4 mice/group). In Figure 4B, the presence of inva-
sive orthotopic tumor was confirmed by an in vivo imaging system. 
Tumor volumes were monitored on the indicated days. As shown in 
Figure 4A,C, relative tumor volumes in the combination group were 
lower than those in the vehicle group or in the AZD6244 group. 
AZD6244 treatment alone did not show a significant effect on tumor 
growth, whereas cotreatment with AZD6244 and PD173074 led to 
tumor regression. H&E staining showed that vehicle and AZD6244- 
treated tumors showed significantly greater tumor cellularities and 
sizes versus mice given combination treatment (Figure 4D). The 
molecular events were explored by immunohistochemical analysis. 
Enhanced levels of Ki67 and p- FGFR3 were found in tumors of the 
vehicle- control and AZD6244 groups, indicating strong cell prolif-
eration in the tumor masses (Figure 4E, magnified images and Allred 
scores can be seen in Figure S6 and Table S2). In contrast, combi-
nation treatment with AZD6244 and PD173074 resulted in a sig-
nificant decline in the levels of Ki67 and p- FGFR3, which was the 
result of inhibited tumor cell proliferation. Prevalence of apoptotic 
F IGURE  3 MEK inhibition and fibroblast growth factor receptor 3 (FGFR3) inhibition induced apoptotic cell death in head and neck 
squamous cell carcinoma (HNSCC) cells treated with AZD6244. A, Cell cycle distribution in Cal27 cells treated with AZD6244 or AZD6244 
plus PD173074 for 24 h. Cell cycle progression was measured by flow cytometry using propidium iodide (PI) to stain DNA. Each value 
represents the mean ± SEM from three independent experiments carried out in triplicate. B, FGFR3, Akt, ERK, and caspase 3 expression 
in Cal27 cells treated with AZD6244 alone or with AZD6244 plus PD173074 for the indicated times are shown in representative western 
blot images. HNSCC cell lines were treated with 0.5 μmol/L AZD6244 alone or with 0.5 μmol/L AZD6244 plus 1 μmol/L PD173074 for the 
indicated times. GAPDH was detected as a loading control. C, Apoptosis of Cal27 cells treated with AZD6244 alone or with combination 
AZD6244 and PD173074 treatment for 24 h. Cells were analyzed by flow cytometry using Annexin V/PI double staining. Graph shows 
the percentage of annexin V- positive, PI- negative cells in terms of mean ± SEM (n = 3 replicates). Significant difference compared to the 
corresponding control, *P  < .05. D, TUNEL staining in Cal27 cells exposed to AZD6244 or PD173074. Cells were treated with 0.1% DMSO, 
AZD6244 alone, PD173074 alone, or AZD6244 plus PD173074 for 24 h, after which TUNEL staining was carried out. Results shown 
represent data from experiments carried out in triplicate
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cells in tumors in the combination- treatment group was significantly 
higher than in tumors from vehicle- control or AZD6244- treated 
mice, as shown by cleaved caspase 3 staining. Treatment of mice 
with PD173074 only showed no effect on histology or apoptosis in 
a group of four treated mice. These results suggested that combi-
nation treatment with both the MEK inhibitor and the FGFR inhibi-
tor had a stronger effect on tumor growth and metastasis than did 
monotherapy with either agent alone.
4  | DISCUSSION
Targeted single- agent therapies that block highly oncogenic func-
tions have a major limitation in that acquired resistance involves high 
levels of feedback activation of the related signaling network. The 
relative insensitivity of BRAF V600E- mutated melanoma to BRAF 
inhibition emerges through an enhanced level of cyclin D1.18 Cyclin E 
overexpression confers insensitivity of trastuzumab in Her2+ breast 
cancer cells.19 The lack of responsiveness of BRAFV600E- positive 
colorectal cancer cells to BRAF inhibition is associated with the 
feedback activation of EGFR.20 ERK 1/2- pathway reactivation dur-
ing acquired resistance has led to the identification of gatekeeper 
mutations in oncogenic kinases promoting the use of the alterna-
tive MEK pathway. Shi et al21 reported that the acquired resistance 
of melanoma cells to BRAF inhibition can result in amplification of 
V600E BRAF expression. Enhanced CRAF levels drive resistance 
to BRAF inhibitors in melanoma.22 COT expression also confers 
acquired resistance to RAF inhibition by triggering a MAP kinase 
switch.23 However, as mentioned above, cyclins D1, E, and G1 or the 
RTK EGFR have been correlated with acquired resistance and could 
emerge as common pathways involved in sustaining ERK 1/2 activa-
tion in tumor cells. Approximately 30% of acquired resistance cases 
emerged independently of remarkable mutations.24
In the present study, we observed that ERK reactivation was 
invoked by FGFR3 activation to counteract the MEK inhibitor in 
HNSCC cells. We used AZD6244 as a selective MEK inhibitor and 
observed an ERK- activity rebound in AZD6244- treated HNSCC 
cell lines. In this experiment, we found that MEK inhibition in-
duced FGFR3 activation. Inhibition of MEK with the FGFR3 in-
hibitor relieved the reactivation of ERK and the insensitivity of 
cancer cells against the MEK inhibitor. This likely occurred in vivo 
in xenograft mice and increased the anticancer effect of the MEK 
inhibitor. Thus, FGFR3 activation in response to MEK inhibition 
caused feedback activation of the ERK 1/2 cascade when FGFR3 
was phosphorylated and Akt was activated. When FGFR3 activa-
tion was suppressed by FGFR siRNA or PD173074, these results 
were not observed. Recently, it was reported that ERK reactiva-
tion in tumors induced extensive and complex feedback activa-
tion of RTK. Prahallad et al20 reported that ERK reactivation by a 
BRAF inhibitor caused induction of RTK and the EGFR pathway. 
These data also indicated that combined treatment with a BRAF 
inhibitor and cetuximab synergistically inhibited tumor growth 
in vivo.20
Recent findings showed that FGFR dysregulation plays an im-
portant role in many cancers. Recently, Marshall et al25 reported 
that FGF- FGFR signaling frequently occurs in HNSCC and was 
dominant or codominant with EGFR in HNSCC. Bevacizumab- 
resistant HNSCC showed upregulated FGF2 and FGFR3 by in-
creased ERK signaling.26 FGF- FGFR autocrine loop signaling was 
induced after chronic adaptation to gefitinib and, thus, FGFR1- 
specific tyrosine kinase inhibitor (TKI) prevented acquired resis-
tance to gefitinib.27 We also showed that induction of the FGF2 
ligand and FGFR3 following MEK inhibition promotes ERK reac-
tivation and insensitivity to MEK inhibition. These findings pro-
vide evidence that FGFR signaling could serve as an additional 
candidate for a bypass mechanism in cancer cell lines rendered 
resistant to anticancer drugs.
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F IGURE  4 Fibroblast growth factor receptor 3 (FGFR3) inhibition cooperated with MEK inhibition to inhibit tumor growth in orthotopic 
xenograft mice. A, Primary tumor growth of Cal27 cells in xenograft mice injected with the indicated inhibitors. Cal27 cells were injected s.c. 
into the tongues of nude mice (n = 4/group). The mice were treated twice per week for 28 d by i.p. injection with DMSO (vehicle control), 
20 mg/(kg day) AZD6244, 10 mg/(kg day) PD173074, or 10 mg/(kg day) PD173074 at 1 d post- injection of 20 mg/(kg day) AZD6244. B, 
In vivo imaging system (IVIS) images of tumors in the tongue at 52 d post- injection. The tumor was detected by in vivo fluorescence imaging 
analysis, as described in Materials and Methods. C, Tumor volumes of mice (n = 4/group) were measured with a caliper on the indicated days. 
Each value represents mean ± SEM between replicates (n = 4/group). D, H&E staining of tumor tissue in a mouse model. Magnification, 40× 
or 100×. Scale bar = 100 μm or 60 μm. E, Ki67, phospho- FGFR3, phospho- Akt, phospho- ERK, and cleaved caspase- 3 expression in tumor 
tissues were measured by immunohistochemistry. Magnification, 100×. Scale bar =  60 μm.
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